Skip to main content

Rakesh Jhunjhunwala picked these stocks in June quarter; total holding stood at Rs 11,549 crore

Jhunjhunwala raised his holding in Rallis India, Federal Bank, Edelweiss Financial Services, NCC, Jubilant Life Sciences, Delta Corp and Firstsource Solutions (FSL), while cut his stake in Lupin and Agro Tech Foods

During the April-June quarter when the domestic stock market was grappling with the impact of coronavirus pandemic, billionaire Rakesh Jhunjhunwala was busy picking up stake in the most unpopular, most battered stocks. The ace investor, who is referred as the 'Warren Buffett of India', acquired stake in some small cap stocks such as Dishman Carbogen Amcis, Autoline Industries, and Indian Hotels during the quarter ended June 30, 2020.

 

As per the latest shareholding pattern available on the exchange, Jhunjhunwala hiked his holding in Rallis India, Federal Bank, Edelweiss Financial Services, NCC, Jubilant Life Sciences, Delta Corp and Firstsource Solutions (FSL), while cut his stake in Lupin and Agro Tech Foods.

His stake in 13 other companies, including Titan Company, Escorts, ION Exchange, Crisil, Fortis Healthcare and Orient Cement, Multi Commodity Stock Exchange of India, remained unchanged during the first quarter of the current fiscal.

 

According to corporate shareholdings filed for June 30, 2020, Rakesh Jhunjhunwala publicly holds 33 stocks with a net worth of over Rs 11,549.3 crore, showed data available on Trendlyne, a stock market investment platform. The net worth of Jhunjhunwala has increased by Rs 316.3 crore from Rs 11,233 crore at the end of March quarter.

 

Also Read: Rakesh Jhunjhunwala buys 50 lakh shares of this firm, stock gains 5%

 

Among the fresh portfolio, Jhunjhunwala and his wife Rekha each acquired 1.59 per cent stake or 25 lakh equity shares in Dishman Carbogen Amcis. Together, they hold a 3.18 per cent stake in the small cap company. The Big Bull also added Indian Hotels in his portfolio, acquiring 1.05 per cent stake or 1.25 crore shares in June quarter.

 


Interestingly, it was Autoline Industries, a specialist product development and engineering company, where Rakesh Jhunjhunwala made his highest fresh investment. He purchased 10.20 lakh equity shares or 3.77 stake in the company, while his wife Rekha picked 2.71 per cent or 7.31 lakh equity shares in the company. Together they hold 6.48 per cent shares in Autoline as on June 2020.

 

 

Meanwhile, Jhunjhunwala raised his stake in Rallis India, a subsidiary of Tata Chemicals, by 0.38 per cent during June quarter. He purchased an additional 7.25 lakh equity shares to raise his stake to 10.31 per cent during the April-June period. He holds shares in the Tata Group company through his two accounts -- Rakesh Radheshyam Jhunjhunwala (7.64 per cent) and Rakesh Jhunjhunwala (2.67 per cent), the data of shareholding pattern on BSE showed.

 

Among others, he raised his stake in NCC by 1.23 per cent to 11.45 per cent in the April - June 2020 quarter. He increased his stake In Jubilant Life Sciences by 0.70 per cent to 5.11 per cent, Federal Bank by 0.10 per cent 3.18 per cent, Firstsource Solutions by 0.82 per cent to 2.88 per cent, Edelweiss Financial Services by 0.15 per cent to 1.19 per cent and Delta Corp by 0.06 per cent to 7.44 per cent.

 


Comments

Post a Comment

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...
Post a Comment
Read more

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

  All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...
Post a Comment
Read more

Similar to 2020, D-Street is at record high ahead of Budget 2021; will history repeat itself?

  Experts are of the view that a repeat of 2020 or what happened in March might not be possible but some consolidation cannot be ruled out. Back in March when everyone wanted to write-off 2020 from their books, hope and liquidity supported markets and investor sentiment. Nobody thought that after touching a 3-year low in March 2020, benchmark indices would give double-digit returns by the end of the year. The S&P BSE Sensex and Nifty50 rallied by about 15 percent in 2020 and the big outperformance came from the small and midcap stocks. The rally is still continuing in 2021. The S&P BSE Sensex, which climbed Mount 49K, is up over 3 percent while the Nifty50 is up over 4 percent so far in January. Sensex scaling the 49,000-mark and Nifty50 touching 14,500 levels ahead of the Budget 2021 could make anyone cautious about the strength of the rally. Back in January 2020, both Sensex and Nifty touched fresh highs ahead of Budget, and then the market fell like a pack of cards. The ...
Post a Comment
Read more